UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000046604
Receipt No. R000053101
Scientific Title Effect of continuous intake of dietary components on postprandial substrate metabolism under dietary maintenance conditions
Date of disclosure of the study information 2022/01/13
Last modified on 2022/01/05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effect of continuous intake of dietary components on postprandial substrate metabolism under dietary maintenance conditions
Acronym Effect of continuous intake of dietary components on postprandial substrate metabolism under dietary maintenance conditions
Scientific Title Effect of continuous intake of dietary components on postprandial substrate metabolism under dietary maintenance conditions
Scientific Title:Acronym Effect of continuous intake of dietary components on postprandial substrate metabolism under dietary maintenance conditions
Region
Japan

Condition
Condition Healthy subjects
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the effect on postprandial substrate metabolism during rest and exercise, middle-aged and elderly pre-obese who do not have exercise habits ingest test diets with different dietary components continuously for 4-weeks.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Stable isotope excretion after test meals (during rest), fatty acid conversion, respiratory exchange ratio (during exercise)
Key secondary outcomes (Secondary outcomes)
Postprandial body heat production (during rest), carbohydrate oxidation (during exercise), visceral fat measurement, heart rate variability
(Safety evaluation)
Vital signs, body measurements(weight,BMI), adverse events

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 4-week ingestion of the test food
Wash out(5 weeks or more)
4-week ingestion of the placebo food
Interventions/Control_2 4-week ingestion of the placebo food
Wash out(5 weeks or more)
4-week ingestion of the test food
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
35 years-old <=
Age-upper limit
65 years-old >
Gender Male and Female
Key inclusion criteria 1)Japanese men and women aged between 35 and 65 years old at the time of obtaining written consent.
2)Subject with BMI >=25kg/m2 and <30kg/m2.
3)Non-smoker
4)Subject with alcohol intake less than 30g/day.
5)Subject who has received sufficient explanation of the purpose and content of the research, has the ability to consent.
Key exclusion criteria 1.Subject who is taking medication or under medical treatment due to serious illness.
2.Subject who has experienced chest pain or abnormal pulse at rest.
3.Subject who is under exercise therapy or dietetic therapy.
4.Subject with serious current illness or complications or history such as heart disease, liver disease, kidney disease, cardiovascular disease, blood disease, etc.
5.Subject who is receiving the rheumatism treatment.
6.Subject who frequently has shortness of breath, lightheadedness, dizziness or loss of consciousness.
7.Subject who might has or has a history of drug allergies, food allergies, allergies to test foods, or allergies to raw materials for evaluated foods(soybeans, milk protein, pork).
8.Subject who has difficulty ingesting test foods and evaluation foods.
9.Subject who has a family member who died suddenly of unknown causes.
10.Subject who has been diagnosed as having problems with the legs and hips.
11.Subject who feels pain in their hips, knees, or body when ascending or descending stairs, etc.
12.Subject with knee surgery or disease, or those who use a cane on a daily basis.
13.Subject with current or history of drug or alcohol dependence.
14.Subject who attends a hospital due to mental disorders (depression, etc.) or sleep disorders (Insomnia, sleep apnea syndrome, etc.), or who has a history of mental illness in the past.
15.Subject who exercises for the purpose of maintaining or improving their physical fitness for a total of 60 minutes or more per week.
Target sample size 30

Research contact person
Name of lead principal investigator
1st name Hidemasa
Middle name
Last name Toya
Organization HUMA R&D CORP
Division name Clinical Development Department
Zip code 108-0014
Address Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
TEL 03-3431-1260
Email toya@huma-rd.co.jp

Public contact
Name of contact person
1st name Hidemasa
Middle name
Last name Toya
Organization HUMA R&D CORP
Division name Clinical Development Department
Zip code 108-0014
Address Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
TEL 03-3431-1260
Homepage URL
Email toya@huma-rd.co.jp

Sponsor
Institute HUMA R&D CORP
Institute
Department

Funding Source
Organization The Nisshin OilliO Group, Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Ethics Committees of Yoga Allergy Clinic
Address 4-32-16 Yoga,Setagaya-ku,Tokyo 158-0097 Japan
Tel 03-5491-4478
Email jim@medipharma.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2022 Year 01 Month 13 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2021 Year 12 Month 03 Day
Date of IRB
2021 Year 12 Month 10 Day
Anticipated trial start date
2022 Year 01 Month 14 Day
Last follow-up date
2022 Year 06 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information (Exclusion criteria continued)
16.Subject who performs physical labor for a total of 10 hours or more per week.
17.Subject whose working hours are irregular due to night shifts, etc.
18.Subject with a weight fluctuation of more than +-5 kg within 2 months.
19.Subject who has extremely irregular lifestyle habits such as eating and sleeping.
20.Subject who has an extremely unbalanced diet.
21.Subject who are using or cannot stop using health foods, supplements, or medicines that affect fatigue reduction, fat burning and obesity control.
22.Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study.
23.Subject who has blood collection or donation more than 200mL within the past 1 month or more than 400mL within the past 3 months from the day of the consent acquisition.
24.Subject who plans or wish to donate blood or get vaccinated during the test period. However, this does not apply to vaccination against the new coronavirus.
25.Subject who is planning to get pregnant after the day of informed consent or is currently pregnant and lactating.
26.Subject who has difficulty observing records on various survey forms.
27.Subject who is judged as an inappropriate candidate according to the screening data.
28.Subject who is considered as an inappropriate candidate by the doctor in charge.

Management information
Registered date
2022 Year 01 Month 12 Day
Last modified on
2022 Year 01 Month 05 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053101

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.